Cutter, Gary R.
Article History
First Online: 16 December 2016
Competing interests
: The author is on Data and Safety Monitoring Boards for AMO Pharma Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Neuren, Opko Biologics, Reata Pharmaceuticals, Receptos/Celgene, Sanofi-Aventis, Teva pharmaceuticals, National Heart Lung and Blood Institute (Protocol Review Committee), National Institute of Child Health and Development (OPRU oversight committee). He runs MS Patient Registry, which receives a grant from Consortium of MS Centers. Moreover, he is on Consulting or Advisory Boards for Cerespir, Genzyme, Genentech, Innate Therapeutics, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara, Somahlution, Teva Pharmaceuticals, Transparency Life Sciences, and TG Therapeutics. He is President of Pythagoras, a private consulting company located in Birmingham, Alabama, USA.